Remibrutinib in Sjogren's Syndrome Dr. Michael Putman reports on abstract 1113 presented at ACR22. Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study https://t.co/4UAxMq2z0X https://t.co/kzinfgDGZr

• https://bit.ly/3vLps1E

PHYSICIANS: Current, routine, outpatient clinic visits - do you require masks

FDA Accepts Biologics License Application for CT-P13 SC, a Subcutaneous Formulation of Infliximab (Celltrion) that is approved in other countries. https://t.co/G1OIoqk9ga https://t.co/NEWFNlKhlU

• https://bit.ly/3XgF1Kf

Neutrophil-to-lymphocyte ratio (NLR) was studied in 205 Idiopathic pulmonary fibrosis (IPF) pts - NLR correlated with lung function, & outcomes - NLR >= 2.9 was associated with a significant 2 fold increased risk of mortality https://t.co/FCuKx2NfeC https://t.co/iIb9uIGBAE

• https://bit.ly/3ZoHHHz

Rheumatology Giants in who passed away in 2022: Eric Gall William Wilke John Winfield Peter Simkin Roy Altman Samuel Strober James Fries Robert Lightfoot Bart Lindsley https://t.co/BX3fGBVre7 https://t.co/ToxZOZHOhU

• https://bit.ly/3VVsE5t

For 2023 - what you going to focus on with your patients? Same ole, same ole means youre not getting better. How about focusing on 2 main messages, mine would be patient "STRENGTH" and "COMPLIANCE" (meaning more Rx education) https://t.co/fEIVYk6Z9m

"Taking an idea isn’t theft. Taking an idea is an oxymoron. Ideas belong to all of us" - Seth Godin @ThisIsSethsBlog https://t.co/eY8Tj0c1rF

2022 Rheumatology Year in Review 2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care. https://t.co/L7bUUdHqQF https://t.co/aVSXyzF3yy

• https://bit.ly/3ItVOFN

According to a 2022 Review of Physician and Advanced Practitioner Recruiting Incentives" by Merritt Hawkins, orthopedics has the highest salary & pediatrics the lowest. Rheumatology: Low: $200,000, Average: $258,000, High: $325,000 https://t.co/PmmAj9s2Vq https://t.co/nEzp4pWiG0

• https://bit.ly/3WQXf5h

Reuters reports that in 2021, the median annual price was $180,000 for the 1st 30 drugs FDA approved. In 2022, the median annual cost was $222,003 for newly approved drugs. https://t.co/laxw6DacHr https://t.co/kRM7EbrD72

• https://reut.rs/3XxS1LZ

Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/qXspeRj0eV https://t.co/g7L2OIgFKc https://t.co/egZFKLbNC7 https://t.co/6M3KIG1kTz

• https://bit.ly/3vI5uES
• https://bit.ly/3GrwfSW
• https://bit.ly/3CxtDBM

Hydroxychloroquine significantly lowers Alzheimer’s and dementia risk. Study of g 109,124 #RA pts starting HCQ or MTX. showed an 8-16% lower risk. https://t.co/gV4AYHRwmU https://t.co/crbTu1zr3E

• https://go.nature.com/3QpI0y4

Differential Dx of hyperferritinemia (≥500 μg/) in critically ill ICU pts includes: sepsis, liver disease/failure, hematological malignancy, HLH. Single center study of 2583 patients https://t.co/F5Dz2qpmAy https://t.co/ZWnxHGoQR1

• https://bit.ly/3GohMY7

ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis The guideline is based on a systemic review and network meta-analysis conducted by the ACP Center for Evidence Reviews at the Portland Veteran Affairs Research Foundation. https://t.co/Tx6PnpCEOp https://t.co/AVsnC1yubI

• https://bit.ly/3QlgtNU